We have located links that may give you full text access.
English Abstract
Journal Article
[Percutaneous transluminal angioplasty in the treatment of 79 cases of reno-vascular hypertension].
79 cases of reno-vascular hypertension were treated with percutaneous transluminal angioplasty (PTRA) during 1981-1994. Athrosclerosis as the etiology of renal artery lesions was noted in 14 cases (17.7%), arteritis in 57 (72.2%), and fibro-muscular dysplasia in 8 (10.1%). The success rate of PTRA was 94.8%. The morbidity rate was 3.8%. There was no mortality in this series. The cure-improvement rate after average follow-up of 44.8 months was 73.4%. It was 75.4% in the group of arteritis. We conclude that PTRA should be considered as the first choice for the treatment of renovascular hypertension, especially to the arteritis patients.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app